[
  {
    "ts": null,
    "headline": "Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance",
    "summary": "FOSTER CITY, Calif., December 18, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company’s senior leadership team and report to Chairman and Chief Executive Officer Daniel O’Day.",
    "url": "https://finnhub.io/api/news?id=c81135523030342b7c3b8354969ff14c67f2fe68f72df3ca29e25737e569e7a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766064600,
      "headline": "Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance",
      "id": 137821811,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., December 18, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company’s senior leadership team and report to Chairman and Chief Executive Officer Daniel O’Day.",
      "url": "https://finnhub.io/api/news?id=c81135523030342b7c3b8354969ff14c67f2fe68f72df3ca29e25737e569e7a7"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Valuation After Positive Phase 3 Data for Its Bictegravir–Lenacapavir HIV Regimen",
    "summary": "Gilead Sciences (GILD) just cleared an important milestone: its once daily bictegravir and lenacapavir combo matched Biktarvy in the Phase 3 ARTISTRY 2 trial, with clean safety data that strengthens the longer term HIV pipeline story. See our latest analysis for Gilead Sciences. The stock has cooled a little in the last month, with a 30 day share price return of minus 4.6 percent. That still sits within a strong 32.1 percent year to date share price gain and a 5 year total shareholder return...",
    "url": "https://finnhub.io/api/news?id=6a0dbbd8ce854ee215e85cf27351e2f97e305fa6cf00e3e0dc0da50c7d81d866",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766031895,
      "headline": "Gilead Sciences (GILD) Valuation After Positive Phase 3 Data for Its Bictegravir–Lenacapavir HIV Regimen",
      "id": 137817224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (GILD) just cleared an important milestone: its once daily bictegravir and lenacapavir combo matched Biktarvy in the Phase 3 ARTISTRY 2 trial, with clean safety data that strengthens the longer term HIV pipeline story. See our latest analysis for Gilead Sciences. The stock has cooled a little in the last month, with a 30 day share price return of minus 4.6 percent. That still sits within a strong 32.1 percent year to date share price gain and a 5 year total shareholder return...",
      "url": "https://finnhub.io/api/news?id=6a0dbbd8ce854ee215e85cf27351e2f97e305fa6cf00e3e0dc0da50c7d81d866"
    }
  },
  {
    "ts": null,
    "headline": "Does Gilead Still Offer Value After Its 2025 Surge and Pipeline Progress?",
    "summary": "Wondering if Gilead Sciences is still a smart buy after its big run, or if the stock has already priced in the good news? Here is a breakdown of whether the current share price really lines up with the underlying value. Gilead is flat over the last week and down 2.2% over the past month, but the stock is still up 32.1% year to date and 37.6% over the last year, with gains of 58.2% in 3 years and 156.3% in 5 years. Behind these moves, investors have been reacting to a steady stream of...",
    "url": "https://finnhub.io/api/news?id=358e6977840c8a9043009f5165971377db1e2c64f46ddbdd43f66b4aa80125e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766023973,
      "headline": "Does Gilead Still Offer Value After Its 2025 Surge and Pipeline Progress?",
      "id": 137817225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Wondering if Gilead Sciences is still a smart buy after its big run, or if the stock has already priced in the good news? Here is a breakdown of whether the current share price really lines up with the underlying value. Gilead is flat over the last week and down 2.2% over the past month, but the stock is still up 32.1% year to date and 37.6% over the last year, with gains of 58.2% in 3 years and 156.3% in 5 years. Behind these moves, investors have been reacting to a steady stream of...",
      "url": "https://finnhub.io/api/news?id=358e6977840c8a9043009f5165971377db1e2c64f46ddbdd43f66b4aa80125e4"
    }
  }
]